These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37353935)

  • 21. Ethical and legal issues in psychedelic harm reduction and integration therapy.
    Pilecki B; Luoma JB; Bathje GJ; Rhea J; Narloch VF
    Harm Reduct J; 2021 Apr; 18(1):40. PubMed ID: 33827588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Exploring the subjective experience of rave party participants in Israel who consume psychedelic drugs: a qualitative inquiry.
    Milshteyn Y; Bensimon M
    Harm Reduct J; 2023 Dec; 20(1):176. PubMed ID: 38057811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychedelics and Evidence-based Psychotherapy: A Systematic Review with Recommendations for Advancing Psychedelic Therapy Research.
    Leone L; McSpadden B; DeMarco A; Enten L; Kline R; Fonzo GA
    Psychiatr Clin North Am; 2024 Jun; 47(2):367-398. PubMed ID: 38724126
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Call for evidence-based psychedelic integration.
    Greń J; Gorman I; Ruban A; Tylš F; Bhatt S; Aixalà M
    Exp Clin Psychopharmacol; 2024 Apr; 32(2):129-135. PubMed ID: 38010760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychedelic Knowledge and Opinions in Psychiatrists at Two Professional Conferences: An Exploratory Survey.
    Barnett BS; Beaussant Y; King F; Doblin R
    J Psychoactive Drugs; 2022; 54(3):269-277. PubMed ID: 34409921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety considerations in the evolving legal landscape of psychedelic-assisted psychotherapy.
    Mocanu V; Mackay L; Christie D; Argento E
    Subst Abuse Treat Prev Policy; 2022 May; 17(1):37. PubMed ID: 35568884
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acid liberalism: Silicon Valley's enlightened technocrats, and the legalization of psychedelics.
    Tvorun-Dunn M
    Int J Drug Policy; 2022 Dec; 110():103890. PubMed ID: 36279734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. (De)criminalisation of psychedelics in the Czech Republic-Where are we heading in drug policy and legislation?
    Dleštíková T
    Int J Drug Policy; 2022 Dec; 110():103900. PubMed ID: 36347160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Relationship Between Naturalistic Psychedelic Use and Clinical Care in Canada.
    Glynos NG; Kruger DJ; Kolbman N; Boehnke K; Lucas P
    J Psychoactive Drugs; 2023; 55(5):660-671. PubMed ID: 37516904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. What can neuroscience tell us about the potential of psychedelics in healthcare? How the neurophenomenology of psychedelics research could help us to flourish throughout our lives, as well as to enhance our dying.
    Mackenzie R
    Curr Drug Abuse Rev; 2014; 7(3):136-45. PubMed ID: 25563449
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world.
    Lake S; Lucas P
    Int J Drug Policy; 2024 Aug; 130():104507. PubMed ID: 38936219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers.
    Erritzoe D; Smith J; Fisher PM; Carhart-Harris R; Frokjaer VG; Knudsen GM
    J Psychopharmacol; 2019 Sep; 33(9):1068-1075. PubMed ID: 30816797
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Embedding existential psychology within psychedelic science: reduced death anxiety as a mediator of the therapeutic effects of psychedelics.
    Moreton SG; Szalla L; Menzies RE; Arena AF
    Psychopharmacology (Berl); 2020 Jan; 237(1):21-32. PubMed ID: 31784805
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How psychedelic researchers' self-admitted substance use and their association with psychedelic culture affect people's perceptions of their scientific integrity and the quality of their research.
    Forstmann M; Sagioglou C
    Public Underst Sci; 2021 Apr; 30(3):302-318. PubMed ID: 33356921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The renaissance in psychedelic research: What do preclinical models have to offer.
    Murnane KS
    Prog Brain Res; 2018; 242():25-67. PubMed ID: 30471682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020.
    Barnett BS; Parker SE; Weleff J
    Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meditation trips: A thematic analysis of the combined naturalistic use of psychedelics with meditation practices.
    Azmoodeh K; Thomas E; Kamboj SK
    Exp Clin Psychopharmacol; 2023 Jun; 31(3):756-767. PubMed ID: 36534415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The prescription of psychedelic therapies in Australia and New Zealand: A brief survey of psychiatrists.
    Berger JJ; Fitzgerald PB
    Australas Psychiatry; 2023 Apr; 31(2):190-194. PubMed ID: 36779819
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.